Top

22-03-2016 | Pediatric lymphoma | Article

Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma

Journal: Pediatric Radiology

Authors: Maria Rosana Ponisio, Jonathan McConathy, Richard Laforest, Geetika Khanna

Publisher: Springer Berlin Heidelberg

Abstract

Background

Whole-body ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard of care for lymphoma. Simultaneous PET/MRI (magnetic resonance imaging) is a promising new modality that combines the metabolic information of PET with superior soft-tissue resolution and functional imaging capabilities of MRI while decreasing radiation dose. There is limited information on the clinical performance of PET/MRI in the pediatric setting.

Objective

This study evaluated the feasibility, dosimetry, and qualitative and quantitative diagnostic performance of simultaneous whole-body FDG-PET/MRI in children with lymphoma compared to PET/CT.

Materials and methods

Children with lymphoma undergoing standard of care FDG-PET/CT were prospectively recruited for PET/MRI performed immediately after the PET/CT. Images were evaluated for quality, lesion detection and anatomical localization of FDG uptake. Maximum and mean standardized uptake values (SUV_max/mean) of normal organs and SUV_max of the most FDG-avid lesions were measured for PET/MRI and PET/CT. Estimation of radiation exposure was calculated using specific age-related factors.

Results

Nine PET/MRI scans were performed in eight patients (mean age: 15.3 years). The mean time interval between PET/CT and PET/MRI was 51 ± 10 min. Both the PET/CT and PET/MRI exams had good image quality and alignment with complete (9/9) concordance in response assessment. The SUVs from PET/MRI and PET/CT were highly correlated for normal organs (SUV_mean r²: 0.88, P<0.0001) and very highly for FDG-avid lesions (SUV_max r²: 0.94, P=0.0002). PET/MRI demonstrated an average percent radiation exposure reduction of 39% ± 13% compared with PET/CT.

Conclusion

Simultaneous whole-body PET/MRI is clinically feasible in pediatric lymphoma. PET/MRI performance is comparable to PET/CT for lesion detection and SUV measurements. Replacement of PET/CT with PET/MRI can significantly decrease radiation dose from diagnostic imaging in children.

Kluge R, Kurch L, Montravers F et al (2013) FDG PET/CT in children and adolescents with lymphoma. Pediatr Radiol 43:406–417CrossRefPubMed

London K, Cross S, Onikul E et al (2011) 18F-FDG PET/CT in paediatric lymphoma: comparison with conventional imaging. Eur J Nucl Med Mol Imaging 38:274–284CrossRefPubMed

Cheng G, Servaes S, Zhuang H (2013) Value of ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan versus diagnostic contrast computed tomography in initial staging of pediatric patients with lymphoma. Leuk Lymphoma 54:737–742CrossRefPubMed

Burkhardt B, Zimmermann M, Oschlies I et al (2005) The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 131:39–49CrossRefPubMed

Sherief LM, Elsafy UR, Abdelkhalek ER et al (2015) Hodgkin lymphoma in childhood: clinicopathological features and therapy outcome at 2 centers from a developing country. Medicine 94: e670CrossRefPubMedPubMedCentral

Ahmed BA, Connolly BL, Shroff P et al (2010) Cumulative effective doses from radiologic procedures for pediatric oncology patients. Pediatrics 126:e851–e858CrossRefPubMed

Kwee TC, Vermoolen MA, Akkerman EA et al (2014) Whole-body MRI, including diffusion-weighted imaging, for staging lymphoma: comparison with CT in a prospective multicenter study. J Magn Reson Imaging 40:26–36CrossRefPubMed

Adams HJ, Kwee TC, Lokhorst HM et al (2014) Potential prognostic implications of whole-body bone marrow MRI in diffuse large B-cell lymphoma patients with a negative blind bone marrow biopsy. J Magn Reson Imaging 39:1394–1400CrossRefPubMed

Siegel MJ, Acharyya S, Hoffer FA et al (2013) Whole-body MR imaging for staging of malignant tumors in pediatric patients: results of the American College of Radiology Imaging Network 6660 Trial. Radiology 266:599–609CrossRefPubMedPubMedCentral

10.

Knopp MV, von Tengg-Kobligk H, Choyke PL (2003) Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring. Mol Cancer Ther 2:419–426PubMed

11.

Histed SN, Lindenberg ML, Mena E et al (2012) Review of functional/anatomical imaging in oncology. Nucl Med Commun 33:349–361CrossRefPubMedPubMedCentral

12.

Kwee TC, Takahara T, Ochiai R et al (2010) Complementary roles of whole-body diffusion-weighted MRI and 18F-FDG PET: the state of the art and potential applications. J Nucl Med 51:1549–1558CrossRefPubMed

13.

Kwee TC, Takahara T, Luijten PR et al (2010) ADC measurements of lymph nodes: inter- and intra-observer reproducibility study and an overview of the literature. Eur J Radiol 75:215–220CrossRefPubMed

14.

Prenzel KL, Monig SP, Sinning JM et al (2003) Lymph node size and metastatic infiltration in non-small cell lung cancer. Chest 123:463–467CrossRefPubMed

15.

Fueger BJ, Yeom K, Czernin J et al (2009) Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin’s lymphoma. Mol Imaging Biol 11:269–274CrossRefPubMedPubMedCentral

16.

Buchbender C, Heusner TA, Lauenstein TC et al (2012) Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med 53:1244–1252CrossRefPubMed

17.

Littooij AS, Kwee TC, Barber I et al (2014) Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard. Eur Radiol 24:1153–1165CrossRefPubMed

18.

Drzezga A, Souvatzoglou M, Eiber M et al (2012) First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 53:845–855CrossRefPubMed

19.

Tian J, Fu L, Yin D et al (2014) Does the novel integrated PET/MRI offer the same diagnostic performance as PET/CT for oncological indications? PLoS One 9, e90844CrossRefPubMedPubMedCentral

20.

Hirsch FW, Sattler B, Sorge I et al (2013) PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner. Pediatr Radiol 43:860–875CrossRefPubMedPubMedCentral

21.

Schafer JF, Gatidis S, Schmidt H et al (2014) Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial results. Radiology 273:220–231CrossRefPubMed

22.

Martinez-Moller A, Souvatzoglou M, Delso G et al (2009) Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med 50:520–526CrossRefPubMed

23.

Meignan M, Gallamini A, Haioun C (2009) Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma 50:1257–1260CrossRefPubMed

24.

Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586CrossRefPubMed

25.

Shah B, Srivastava N, Hirsch AE et al (2012) Intra-reader reliability of FDG PET volumetric tumor parameters: effects of primary tumor size and segmentation methods. Ann Nucl Med 26:707–714CrossRefPubMed

26.

ICRP (2008) Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. Ann ICRP 38:1–197CrossRefPubMed

27.

Theocharopoulos N, Damilakis J, Perisinakis K et al (2006) Estimation of effective doses to adult and pediatric patients from multislice computed tomography: a method based on energy imparted. Med Phys 33:3846–3856CrossRefPubMed

28.

Mukaka MM (2012) Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med J 24:69–71PubMedPubMedCentral

29.

Biederer J, Hintze C, Fabel M (2008) MRI of pulmonary nodules: technique and diagnostic value. Cancer Imaging 8:125–130CrossRefPubMedPubMedCentral

30.

Heusch P, Buchbender C, Beiderwellen K et al (2013) Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI. Eur J Radiol 82:870–876

31.

Heacock L, Weissbrot J, Raad R et al (2015) PET/MRI for the evaluation of patients with lymphoma: initial observations. AJR Am J Roentgenol 204:842–848CrossRefPubMedPubMedCentral

32.

Lyons K, Seghers V, Sorensen JI et al (2015) Comparison of standardized uptake values in normal structures between PET/CT and PET/MRI in a tertiary pediatric hospital: a prospective study. AJR Am J Roentgenol 205:1094–1101CrossRefPubMed

33.

Westerterp M, Pruim J, Oyen W et al (2007) Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging 34:392–404CrossRefPubMed

34.

Delso G, Furst S, Jakoby B et al (2011) Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med 52:1914–1922CrossRefPubMed

35.

Jakoby BW, Bercier Y, Watson CC et al (2009) Performance characteristics of a new LSO PET/CT scanner with extended axial field-of-view and PSF reconstruction. IEEE Trans Nucl Sci 56:633–639CrossRef

36.

Chin BB, Green ED, Turkington TG et al (2009) Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3h. Mol Imaging Biol 11:118–122CrossRefPubMed

37.

Keller SH, Holm S, Hansen AE et al (2013) Image artifacts from MR-based attenuation correction in clinical, whole-body PET/MRI. MAGMA 26:173–181CrossRefPubMed

38.

Wurslin C, Schmidt H, Martirosian P et al (2013) Respiratory motion correction in oncologic PET using T1-weighted MR imaging on a simultaneous whole-body PET/MR system. J Nucl Med 54:464–471CrossRefPubMed

39.

Nehmeh SA, Erdi YE, Ling CC et al (2002) Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer. Med Phys 29:366–371CrossRefPubMed

40.

Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571–578CrossRefPubMed

41.

Weiler-Sagie M, Bushelev O, Epelbaum R et al (2010) (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 51:25–30CrossRefPubMed